Novo Nordisk Should Have Studied Insulin Icodec Twice-Weekly Dosing, US Panel Says

FDA had recommended studying a twice-weekly dose, but Novo declined because it would add complexity to treatment for type 1 diabetes. However, the firm’s proposed strategy for reducing hypoglycemia risk with once-weekly insulin icodec would create its own complexity, panel said.

Complexity
Novo Nordisk said a twice-weekly insulin icodec regimen would have created too much complexity. • Source: Shutterstock

Novo Nordisk’s decision not to study a twice-weekly dose of insulin icodec because it would add treatment complexity rang hollow to the US Food and Drug Administration’s external experts who said the once-weekly dosing regimen had a negative benefit-risk profile in type 1 diabetes.

Key Takeaways
  • Novo chose not to follow FDA’s recommendation that it add a twice-weekly insulin icodec arm to the pivotal trial in type 1 diabetes.

  • Company said dosing twice, instead of once, a week would have added too much complexity to T1D treatment

Contrary to FDA advice, Novo opted not to include a twice-weekly insulin icodec arm in the Phase III trial because having to administer the basal insulin two times a week

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA Performance Tracker

More from Regulatory Trackers